Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Multiple Sclerosis Centers of Excellence

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

Siponimod (Mayzent)

Siponimod (Mayzent) is an oral treatment for relapsing forms of MS to include, relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome. Dosing of siponimod is based on test results for CYP2C9 genotype. Siponimod is contraindicated in those with CYP2C9*3/3* genotype. Siponimod acts on the sphingosine 1-phosphate receptor modulator with high affinity for the S1P1 and S1P5 receptors by blocking the migration of lymph cells from lymph nodes.

Additional Information

Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.

return to top go